Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

March 6, 2022

Study Completion Date

March 6, 2022

Conditions
Type 2 Diabetes Mellitus
Interventions
DEVICE

Omnipod 5 Automated Insulin Delivery System

"The Omnipod 5 is a single hormone insulin delivery system intended for the management of diabetes in persons requiring insulin. Continuous subcutaneous insulin infusion may be delivered by user-defined settings (manual mode) or automatically adjusted in response to feedback from a continuous glucose monitor (CGM).~The Omnipod 5 can automatically increase insulin delivery based on sensor glucose values from the continuous glucose monitor (CGM) and can decrease or suspend delivery of insulin when the glucose value falls below or is predicted to fall below predefined threshold values.~The Omnipod 5 is designed to assist patients with diabetes in achieving glycemic targets set by their health care providers."

Trial Locations (4)

30303

Emory University, Atlanta

30318

Atlanta Diabetes, Atlanta

55416

International Diabetes Center, Saint Louis Park

90022

University of California, Los Angeles

Sponsors
All Listed Sponsors
lead

Insulet Corporation

INDUSTRY

NCT04617795 - Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter